$IOVA Iovance Biotherapeutics is once again being mentioned as a potential M&A target, this time for Johnson & Johnson and Pfizer: https://t.co/UjOsmmR4Rg
We don't know whether Iovance is for sale, but we do know that it is on many big pharmas' radar.
The thesis is simple: